MUC2 and colitis: By contrast, IL-18 treatment at a later stage of the disease enhanced inflammatory infiltration and reduced Muc-2 expression, decreased the function and quantity of goblet cells, suggesting the anti-inflammatory effect of IL-18 at the early stage of colitis-induced inflammation [71].